Quick Answer
CytomX Therapeutics, Inc. reported Total Revenue of $76.20 million for fiscal year 2025.
CytomX Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $76.20M -44.8% |
$138.10M +36.4% |
$101.21M +90.4% |
$53.16M +42.5% |
$37.31M -62.8% |
$100.36M +74.6% |
| Revenue (ASC 606) | $76.20M -44.8% |
$138.10M +36.4% |
$101.21M +90.4% |
$53.16M +42.5% |
$37.31M -62.8% |
$100.36M +74.6% |
| Net Income | -$17.37M -154.5% |
$31.87M +5700.9% |
-$569.0K +99.4% |
-$99.32M +14.3% |
-$115.87M -252.3% |
-$32.88M +67.8% |
| Total Assets | $151.57M +25.7% |
$120.53M -40.3% |
$201.79M -22.7% |
$260.89M -23.1% |
$339.41M -5.4% |
$358.66M +5.1% |
| Cash and Equivalents | $12.67M -66.7% |
$38.05M +121.6% |
$17.17M -91.1% |
$193.65M -5.8% |
$205.53M +7.1% |
$191.86M +1.8% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $99.01M +21812.3% |
-$456.0K +99.0% |
-$47.45M -59.5% |
-$29.74M -6379.1% |
-$459.0K +94.1% |
-$7.77M -115.2% |
| R&D Expense | $68.73M -17.6% |
$83.38M +7.3% |
$77.68M -30.4% |
$111.65M -2.2% |
$114.19M +1.1% |
$112.94M -14.2% |
| Operating Income | -$22.36M -189.5% |
$25.00M +485.5% |
-$6.48M +93.6% |
-$101.33M +12.7% |
-$116.04M -138.7% |
-$48.60M +56.2% |
| Shares Outstanding | 170.19M +112.5% |
80.10M +19.0% |
67.31M +1.6% |
66.23M +1.3% |
65.39M +35.5% |
48.25M +6.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.96M | -82.2% | -68.0% |
| Revenue (ASC 606) | September 30, 2025 | $5.96M | -82.2% | -68.0% |
| Net Income | September 30, 2025 | -$14.23M | -348.1% | -9139.6% |
| Total Assets | September 30, 2025 | $158.25M | +13.9% | -9.6% |
| Cash and Equivalents | September 30, 2025 | $34.19M | -15.8% | -30.3% |
| Long-Term Debt | December 31, 2014 | $1.57M | — | — |
| Stockholders Equity | September 30, 2025 | $107.39M | +557.9% | -10.4% |
| R&D Expense | September 30, 2025 | $15.30M | -28.4% | +14.9% |
| Operating Income | September 30, 2025 | -$15.77M | -483.6% | -1126.1% |
| Shares Outstanding | September 30, 2022 | 65.95M | +1.1% | +0.3% |
- CytomX Therapeutics, Inc. reported Total Revenue of $76.20 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed a decrease of -44.8% in Total Revenue compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Revenue (ASC 606) of $76.20 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed a decrease of -44.8% in Revenue (ASC 606) compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Net Income of -$17.37 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed a decrease of -154.5% in Net Income compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Total Assets of $151.57 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed an increase of +25.7% in Total Assets compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Cash and Equivalents of $12.67 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed a decrease of -66.7% in Cash and Equivalents compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Long-Term Debt of $1.57 million for fiscal year 2014.
- CytomX Therapeutics, Inc. reported Stockholders Equity of $99.01 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed an increase of +21812.3% in Stockholders Equity compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported R&D Expense of $68.73 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed a decrease of -17.6% in R&D Expense compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Operating Income of -$22.36 million for fiscal year 2025.
- CytomX Therapeutics, Inc. showed a decrease of -189.5% in Operating Income compared to the prior fiscal year.
- CytomX Therapeutics, Inc. reported Shares Outstanding of 170.19 million shares for fiscal year 2025.
- CytomX Therapeutics, Inc. showed an increase of +112.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: